A- A A+

Use of Generally Recognized as Safe or Dietary Compounds to Inhibit Buprenorphine Metabolism: Potential to Improve Buprenorphine Oral Bioavailability.

Maharao N, Venitz J, Gerk PM.

Biopharm Drug Dispos. 2018 Dec 5. doi: 10.1002/bdd.2166. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30520057

Care-by-parent model as a tool for reduction in neonatal opioid withdrawal syndrome in neonates exposed to buprenorphine maintenance therapy in-utero.

Lawlor ML, Shook L, McQuerry K, Srinivasan A, Johnson QB, Chavan NR, Critchfield AS.

J Matern Fetal Neonatal Med. 2018 Dec 18:1-111. doi: 10.1080/14767058.2018.1558201.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30563376

Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine.

Gilman M, Li L, Hudson K, Lumley T, Myers G, Corte C, Littlewood R.

Patient Prefer Adherence. 2018 Oct 11;12:2123-2129. doi: 10.2147/PPA.S180641. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188959/

Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence.

Wakeman SE, Chang Y, Regan S, Yu L, Flood J, Metlay J, Rigotti N.

J Addict Med. 2018 Dec 13. doi: 10.1097/ADM.0000000000000486.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30550392

Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder.

Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA.

Subst Abuse Rehabil. 2018 Sep 21;9:59-78. doi: 10.2147/SAR.S150253.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165853/

Single high-dose buprenorphine for opioid craving during withdrawal.

Ahmadi J, Jahromi MS, Ghahremani D, London ED.

Trials. 2018 Dec 10;19(1):675. doi: 10.1186/s13063-018-3055-z.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288888/

High buprenorphine-related mortality is persistent in Finland.

Kriikku P, Häkkinen M, Ojanperä I.

Forensic Sci Int. 2018 Aug 17;291:76-82. doi: 10.1016/j.forsciint.2018.08.010. 

Abstract

https://www.sciencedirect.com/science/article/pii/S0379073818305073?via%3Dihub

Intravenous buprenorphine/naloxone and concomitant oral pregabalin misuse: a case report.

Kulaksızoğlu B, Kara H, Bodur B, Kuloğlu M.

Neuropsychiatr Dis Treat. 2018 Nov 9;14:3033-3035. doi: 10.2147/NDT.S179688. eCollection 2018.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233699/

Buprenorphine Formulations for the Treatment of Opioid Use Disorders: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines [Internet].

Harricharan S, Farah K.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jul 31.

https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0099978/

Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.

Fava M, Memisoglu A, Thase ME, Bodkin JA, Trivedi MH, de Somer M, Du Y, Leigh-Pemberton R, DiPetrillo L, Silverman B, Ehrich E.

Am J Psychiatry. 2016 May 1;173(5):499-508. doi: 10.1176/appi.ajp.2015.15070921.

https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2015.15070921

USA. FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence

Agency is taking additional steps to advance the development of new FDA-approved treatments for opioid dependence and encourage their more widespread use. 

The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. This action provides a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film, which is also approved in both brand name and generic versions and in various strengths. (FDA - U.S. Food and Drug Administration, 07.09.2018)

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm619864.htm

EU-Zulassung für Buprenorphin-Depotlösung 

Berlin- Methadon, Levomethadon, Buprenorphin und Diamorphin können zur Substitutionstherapie opioidabhängiger Patienten eingesetzt werden. In Europa wurde nun die erste Buprenorphin-haltige Depotinjektion zugelassen, die Markteinführung in den einzelnen Ländern ist für das erste Quartal 2019 geplant. (APOTHEKE ADHOC, 04.12.2018)

https://www.apotheke-adhoc.de/nachrichten/detail/pharmazie/eu-zulassung-fuer-buprenorphin-depotloesung-opioidabhaengigkeit/

USA. OxyContin maker gets patent for drug to treat opioid addiction

Purdue Pharma, the maker of OxyContin, has received a patent designed to treat opioid addiction.

The patent, first reported by The Financial Times, is for a new and faster-acting form of buprenorphine. (CBS-News, Money Watch, USA, 07.08.2018)

https://www.cbsnews.com/news/oxycontin-maker-receives-patent-for-drug-to-treat-opioid-addiction/

A clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteers. 

Strand, M. C., Vindenes, V., Gjerde, H., Mørland, J. G., and Ramaekers, J. G. (2018) 

Br J Clin Pharmacol, doi.org/10.1111/bcp.13818

https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/bcp.13818

USA. OxyContin Billionaire Patents New Drug for Opioid Treatment

In recent years, America’s pharmaceutical industry has taken it on the chin. Populist demagogues have savaged drug companies for “jacking up” the price of life-saving substances like insulin (a.k.a. honoring their fiduciary duty to maximize shareholder value). These boisterous neo-Bolsheviks will point to the fact that pharmaceuticals are several times more expensive in the U.S. than in other countries, and conclude that our government’s exceptionally strong patent laws — and aberrant refusal to push down drug prices through direct negotiation — are meant to enrich Big Pharma at the working American’s expense. (Daily Intelligencer, USA, 07.09.2018)

http://nymag.com/daily/intelligencer/2018/09/richard-sackler-oxycontin-billionaire-patent-opioid-addiction-treatment-buprenorphine.html

Utilizing Buprenorphine in the Emergency Department after Overdose

Johns, Sade E. et al.

Trends in Pharmacological Sciences , Volume 39 , Issue 12 , 998 - 1000 

https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(18)30180-9

MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.

Schuman-Olivier Z, Borodovsky JT, Steinkamp J, Munir Q, Butler K, Greene MA, Goldblatt J, Xie HY, Marsch LA.

Addict Sci Clin Pract. 2018 Sep 24;13(1):21. doi: 10.1186/s13722-018-0122-4.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154900/

Efficacy of buprenorphine and clonidine in opioid detoxification: A hospital- based study.

Jain N, Chavan BS, Sidana A, Das S.

Indian J Psychiatry. 2018 Jul-Sep;60(3):292-299. doi: 10.4103/psychiatry.IndianJPsychiatry_381_17.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201659/

The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.

Ahmadi J, Jahromi MS, Ehsaei Z.

Trials. 2018 Aug 29;19(1):462. doi: 10.1186/s13063-018-2843-9.

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2843-9

Camurus: Die Europäische Kommission erteilt die Marktzulassung für wöchentliche und monatliche Buvidal®-Depotinjektionen zur Behandlung von Opioidabhängigkeit

Lund, Schweden - Buvidal® ist die erste in der EU zugelassene Depotinjektion mit Langzeitwirkung zur Behandlung von Opioidabhängigkeit bei Erwachsenen und Jugendlichen. ((ots/PRNewswire, 22.11.2018)

https://www.presseportal.de/pm/110796/4123405

SAMHSA. Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: Treatment Improvement Protocol: TIP 63.

Substance Abuse and Mental Health Services Administration 
[US] Substance Abuse and Mental Health Services Administration, 2018

https://store.samhsa.gov/shin/content/SMA18-5063FULLDOC/SMA18-5063FULLDOC.pdf

Camurus: Transforming treatments by long-acting medications

Fredrik Tiberg, President & CEO

Pdf-Präsentation zu CAM 2038, Weekly and monthly buprenorphine depots - Changing the treatment paradigm in opioid dependence (ohne Datum)

https://www.camurus.com/wp-content/uploads/2017/12/Camurus-Company-Presentation-CARNEGIE-NYC-171205.pdf

The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review.

Serafini G, Adavastro G, Canepa G, De Berardis D, Valchera A, Pompili M, Nasrallah H, Amore M.

Int J Mol Sci. 2018 Aug 15;19(8). pii: E2410. doi: 10.3390/ijms19082410. 

http://www.mdpi.com/1422-0067/19/8/2410

Treatment of Kratom Withdrawal and Addiction With Buprenorphine.

Khazaeli A, Jerry JM, Vazirian M.

J Addict Med. 2018 Nov/Dec;12(6):493-495. doi: 10.1097/ADM.0000000000000435.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30383616

Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.

Roux P, Rojas Castro D, Ndiaye K, Briand Madrid L, Laporte V, Mora M, Maradan G, Morel S, Spire B, Carrieri P.

Subst Abuse Treat Prev Policy. 2017 Nov 2;12(1):46. doi: 10.1186/s13011-017-0131-4.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667450/

Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.

Azar P, Nikoo M, Miles I.

Am J Addict. 2018 Nov 2. doi: 10.1111/ajad.12809. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30387894

USA. FDA Nixes Approval of Buprenorphine Spray for Pain

Today the US Food and Drug Administration (FDA) turned down approval of Buvaya, a buprenorphine sublingual spray (INSYS Therapeutics) for moderate to severe pain resulting from reported safety concerns. (Medscape, 27.07.2018)

https://www.medscape.com/viewarticle/899924

CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence

On approval, Buvidal® would be the first long-acting medicine for treatment of opioid dependence in the EU

A final decision by the European Commission is expected November 2018. (Camurus, 21.09.2018)

http://news.cision.com/camurus-ab/r/chmp-recommends-approval-of-buvidal---cam2038--for-the-treatment-of-opioid-dependence,c2624232

Buprenorphin-Naloxone: Mundipharma bringt Zubsolv®

Berlin- Die Substitutionstherapie opioidabhängiger Patienten erfolgt durch medizinische, soziale und psychotherapeutische Maßnahmen. Mundipharma bringt mit Zubsolv neue Sublingualtabletten mit Buprenorphin und Naloxon auf den Markt. (apotheke adhoc, 17.05.2018)

https://www.apotheke-adhoc.de/nachrichten/detail/pharmazie/mundipharma-bringt-zubsolv-opioidabhaengigkeit/

Understanding the use of diverted buprenorphine.

Cicero TJ, Ellis MS, Chilcoat HD.

Drug Alcohol Depend. 2018 Oct 12;193:117-123. doi: 10.1016/j.drugalcdep.2018.09.007.

https://www.ncbi.nlm.nih.gov/pubmed/30359928